US biopharma: "nearly 300 vaccines in R&D"

Article Date: 24/04/2012 06:00
US biopharma: "nearly 300 vaccines in R&D"

Vacancy Search

Quick job search

Advanced Search

Latest News

FDA green light for Cubist's antibiotic

FDA green light for Cubist's antibiotic

AZ' novel PARP inhibitor Lynparza bags US approval

AZ' novel PARP inhibitor Lynparza bags US approval

New apps steers patients away from branded cold/flu meds

New apps steers patients away from branded cold/flu meds

NHS England announces new measures to encourage innovation

NHS England announces new measures to encourage innovation

Roche dumps AD trial, Kadcyla first-line disappoints

Roche dumps AD trial, Kadcyla first-line disappoints

First stem-cell therapy among seven drugs up for EU nod

First stem-cell therapy among seven drugs up for EU nod

Twenty-year study proves tamoxifen saves lives

Twenty-year study proves tamoxifen saves lives

Merck & Co gives epigenetics a boost

Not only is Merck & Co’s $110m buyout of OncoEthix a rewarding exit for the private Swiss company’s backers, it also broadly endorses epigenetics – an anticancer approach that has so far...

$50m gift entices Adocia to take Lilly back

Biotech gets big pharma, biotech loses big pharma, biotech gets big pharma back again. This is the story of Lilly’s new partnership with Adocia for the ultrafast insulin BioChaperone Lispro,...

Roche sings so long to Kadcyla in first-line breast cancer

The surprise failure of the Marianne trial will deliver a painful blow to Roche’s campaign of dominance in the Her2 space.
more news